

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6356360

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY AGREEMENT
<b>SEQUENCE:</b>	3

## CONVEYING PARTY DATA

Name	Execution Date
MARAVAI LIFE SCIENCES, INC.	10/19/2020
TRILINK BIOTECHNOLOGIES, LLC	10/19/2020
VECTOR LABORATORIES, INC.	10/19/2020
GLEN RESEARCH, LLC	10/19/2020
CYGNUS TECHNOLOGIES, LLC	10/19/2020
MOCKV SOLUTIONS INC.	10/19/2020

## RECEIVING PARTY DATA

<b>Name:</b>	MORGAN STANLEY SENIOR FUNDING, INC.
<b>Street Address:</b>	1300 THAMES STREET, 4TH FLOOR
<b>Internal Address:</b>	THAMES STREET WHARF
<b>City:</b>	BALTIMORE
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	21231

## PROPERTY NUMBERS Total: 29

Property Type	Number
Patent Number:	10519189
Patent Number:	10494399
Patent Number:	9631227
Patent Number:	6320041
Patent Number:	8361753
Patent Number:	8133669
Patent Number:	8728725
Patent Number:	7102024
Patent Number:	7732628
Patent Number:	RE46171
Patent Number:	6800728
Patent Number:	7462689
Patent Number:	8541555

PATENT

Property Type	Number
Patent Number:	8846875
Patent Number:	6911535
Patent Number:	7999098
Patent Number:	7173125
Patent Number:	6686461
Patent Number:	6770754
Patent Number:	7491817
Patent Number:	8394948
Patent Number:	7144995
Patent Number:	10309963
Patent Number:	9632087
Application Number:	15761957
Application Number:	15970100
Application Number:	16195208
Application Number:	15547094
Application Number:	16386327

#### CORRESPONDENCE DATA

**Fax Number:** (800)914-4240

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 800-713-0755

**Email:** Michael.Violet@wolterskluwer.com, ECarrera@cahill.com

**Correspondent Name:** CT CORPORATION

**Address Line 1:** 4400 EASTON COMMONS WAY

**Address Line 2:** SUITE 125

**Address Line 4:** COLUMBUS, OHIO 43219

**NAME OF SUBMITTER:** ELAINE CARRERA

**SIGNATURE:** /Elaine Carrera/

**DATE SIGNED:** 10/19/2020

#### Total Attachments: 15

source=b10. Maravai - IP Security Agreement (Patents)#page1.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page2.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page3.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page4.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page5.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page6.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page7.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page8.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page9.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page10.tif

source=b10. Maravai - IP Security Agreement (Patents)#page11.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page12.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page13.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page14.tif  
source=b10. Maravai - IP Security Agreement (Patents)#page15.tif

RECORDATION FORM COVER SHEET  
**PATENTS ONLY**

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies)**

Maravai Life Sciences, Inc. MockV Solutions Inc.  
TriLink BioTechnologies, LLC  
Vector Laboratories, Inc.  
Glen Research, LLC  
Cygnus Technologies, LLC

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

**2. Name and address of receiving party(ies)**

Name: Morgan Stanley Senior Funding, Inc.

Internal Address: \_\_\_\_\_

Street Address: 1300 Thames Street, 4th Floor, Thames Street Wharf

City: Baltimore

State: MD

Country: USA Zip: 21231

Additional name(s) & address(es) attached? ☐ Yes ☒ No

**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) October 19, 2020

☐ Assignment

☐ Merger

☒ Security Agreement

☐ Change of Name

☐ Joint Research Agreement

☐ Government Interest Assignment

☐ Executive Order 9424, Confirmatory License

☐ Other \_\_\_\_\_

**4. Application or patent number(s):**

☐ This document serves as an Oath/Declaration (37 CFR 1.63).

A. Patent Application No.(s)

B. Patent No.(s)

See Schedule A

See Schedule A

Additional numbers attached? ☒ Yes ☐ No

**5. Name and address to whom correspondence concerning document should be mailed:**

Name: Elaine Carrera, Senior Paralegal

Internal Address: \_\_\_\_\_

Street Address: c/o Cahill Gordon & Reindel LLP,  
32 Old Slip

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3365

Docket Number: \_\_\_\_\_

Email Address: ecarrera@cahill.com

**6. Total number of applications and patents involved:** 29

**7. Total fee (37 CFR 1.21(h) & 3.41)** \$ \_\_\_\_\_

☐ Authorized to be charged to deposit account

☐ Enclosed

☐ None required (government interest not affecting title)

**8. Payment Information**

Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

Elaine Carrera  
Signature

October 19, 2020

Date

Elaine Carrera

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

15

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1460, Alexandria, V.A. 22313-1460

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) dated as of October 19, 2020, is among the Persons listed on the signature pages hereof (each a “Grantor” and, collectively, the “Grantors”) and MORGAN STANLEY SENIOR FUNDING, INC., as collateral agent (in such capacity, together with any successor collateral agent, the “Collateral Agent”) for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), CYGNUS TECHNOLOGIES, LLC, a Delaware limited liability company (“Cygnus”), TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“TriLink”), VECTOR LABORATORIES, INC., a California corporation (“Vector”; and together with the Parent Borrower, Cygnus and TriLink, the “Borrowers” and each a “Borrower”), MARAVAI TOPCO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), have entered into the Credit Agreement dated as of October 19, 2020 (as amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time, the “Credit Agreement”), with the lenders and financial institutions from time to time party thereto and MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent, Collateral Agent and an L/C Issuer. Capitalized terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, pursuant to the Credit Agreement, each Grantor has executed and delivered that certain Security Agreement dated as of October 19, 2020 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors, the other grantors from time to time party thereto and the Collateral Agent.

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed thereunder to execute this IP Security Agreement for recording with the USPTO and/or the USCO, as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

Section 1. Grant of Security. Each Grantor hereby pledges to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, and each Grantor hereby grants to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantor’s right, title and interest in and to the following, whether now owned or held or hereafter acquired or created by the undersigned (the “Collateral”):

- (i) all Patents, including the patents and patent applications set forth in Schedule A hereto (the “Patent Collateral”);
- (ii) all Trademarks, including the trademark and service mark registrations and applications set forth in Schedule B hereto, together with the goodwill of the business connected with the use thereof and symbolized thereby (the “Trademark Collateral”);

(iii) all Copyrights, whether registered or unregistered, including, without limitation, the copyright registrations and applications set forth in Schedule C hereto (the “Copyright Collateral”);

(iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect such damages, or otherwise recover with respect to such claims; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and Supporting Obligations relating to, any and all of the foregoing or arising from any of the foregoing;

provided that notwithstanding anything to the contrary contained in the foregoing clauses (i) through (vi), the security interest created hereby shall not extend to, and the term “Collateral” shall not include, any Excluded Property, including, for clarity, any United States intent-to-use trademark or service mark applications prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, to the extent that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law.

Section 2. Security for Obligations. The grant of a security interest in the Collateral by each Grantor under this IP Security Agreement secures the payment of all Secured Obligations of such Grantor. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to each Grantor, the payment of all amounts that constitute part of the Secured Obligations that would be owed by such Grantor to any Secured Party under the Secured Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

Section 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks, as applicable, record this IP Security Agreement.

Section 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

Section 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

Section 6. Governing Law; Jurisdiction; Etc.

(a) THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF, BUT INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE COLLATERAL AGENT, ANY LENDER OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT OR THE RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN CLAUSE (b) OF THIS SECTION 6. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP

SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS IP SECURITY AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF SECTION 10.17 OF THE CREDIT AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

[Remainder of page left intentionally blank]




IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

MARAVAI LIFE SCIENCES, INC.;  
TRILINK BIOTECHNOLOGIES, LLC;  
VECTOR LABORATORIES, INC.; and  
GLEN RESEARCH, LLC

By:   
Name: Kevin Herde  
Title: Chief Financial Officer

[Signature Page to Intellectual Property Security Agreement]

CYGNUS TECHNOLOGIES, LLC  
MOCKV SOLUTIONS INC.


By: 

Name: Kevin Herde

Title: Chief Financial Officer

[Signature Page to Intellectual Property Security Agreement]

**MORGAN STANLEY SENIOR FUNDING,  
INC.,**  
as Collateral Agent

By:   
Name: Graham Robertson  
Title: Authorized Signatory

**SCHEDULE A****PATENTS**

<b>Assignee</b>	<b>Title</b>	<b>Country</b>	<b>Issued Date</b>
TriLink BioTechnologies, Inc	Compositions And Methods For Synthesizing 5'-Capped Rnas	United States	10519189 12/31/2019
TriLink BioTechnologies, Inc	Compositions And Methods For Synthesizing 5'-Capped Rnas	United States	10494399 12/03/2019
TriLink BioTechnologies, Inc	Chemically Modified Ligase Cofactors, Donors And Acceptors	United States	9631227 04/25/2017
TriLink BioTechnologies, Inc.	Pre-activated Carbonyl Linkers for the Modification of Oligonucleotides	United States	6320041 11/20/2001
TriLink BioTechnologies	Phosphotriester-Modified Oligonucleotide Primers for Nucleic Acid Amplification	United States	8361753 01/29/2013
TriLink BioTechnologies	Chemically Modified Nucleoside 5'-Triphosphates for Thermally Initiated Amplification of Nucleic Acid	United States	8133669 03/13/2012
TriLink BioTechnologies	Chemically Modified Ligase Cofactors, Donors and Acceptors	United States	8728725 05/20/2014
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	7102024 09/05/2006
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	7732628 06/08/2010
TriLink BioTechnologies, LLC	Functional biopolymer modification reagents and uses thereof	United States	RE46171 10/04/2016
TriLink BioTechnologies, LLC	Hydrazine-based and carbonyl-based bifunctional crosslinking reagents	United States	6800728 10/05/2004


Assignee	Title	Country	Issued Date
TriLink BioTechnologies, LLC	Hydrazine-based and carbonyl-based bifunctional crosslinking reagents	United States	7462689 12/09/2008
TriLink BioTechnologies, LLC	Hydrazone-based and oxime-based fluorescent and chromophoric/pro-flourescent and pro-chromophoric reagents and linkers	United States	8541555 09/24/2013
TriLink BioTechnologies, LLC	Preparation and/or purification of oligonucleotide conjugates	United States	8846875 09/30/2014
TriLink BioTechnologies, LLC	Biomolecule/polymer conjugates	United States	6911535 06/28/2005
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and uses thereof	United States	7999098 08/16/2011
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and uses thereof	United States	7173125 02/06/2007
TriLink BioTechnologies, LLC	Triphosphate oligonucleotide modification reagents and uses thereof	United States	6686461 02/03/2004
Glen Research, LLC (f/k/a Glen Research Corporation)	Universal supports for oligonucleotide synthesis	United States	6770754 8/3/2004
Glen Research, LLC (f/k/a Glen Research Corporation)	Universal supports for oligonucleotide synthesis	United States	7491817 2/17/2009
Glen Research, LLC (f/k/a Glen Research Corporation); Nelson Biotechnologies, Inc.	Novel reagents utilizing a serinol scaffold for labeling synthetic oligonucleotide	United States	8394948 3/12/2013

Assignee	Title	Country	Issued Date
Glen Research, LLC (f/k/a Glen Research Corporation); Berry & Associates	Fluorescent nitrogenous base and nucleosides incorporating same	United States	7144995 12/5/2006
MockV Solutions	Methods and kits for quantifying the removal of mock virus particles from a purified solution	United States	10309963 06/04/2019
MockV Solutions	Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles	United States	9632087 04/25/2017

#### PATENT APPLICATIONS

Assignee	Title	Country	Application Serial No.	Filing Date
TriLink BioTechnologies, Inc.	Compositions And Methods For Synthesizing 5'-Capped Rnas	United States	15/761,957	9/20/2016
Vector Laboratories, Inc.	Immunofluorescence Assays	United States	15/970,100	5/3/2018
Vector Laboratories, Inc.	Methods And Systems For Species-On-Species Immunoassay Detection	United States	16/195,208	11/19/2018
MockV Solutions	Stock solution of retrovirus like particles with method and kit	United States	15547094	07/28/2017
MockV Solutions	Methods and kits for quantifying the removal of mock virus particles from a purified solution	United States	16386327	04/17/2019

**SCHEDULE B****TRADEMARKS**

<b>Owner</b>	<b>Mark</b>	<b>Country</b>	<b>Registration No. / Date</b>
Vector Laboratories, Inc.	Elite	United States	2006391 10/8/1996
Vector Laboratories, Inc.	Photoprobe	United States	1426136 1/27/1987
Vector Laboratories, Inc.	V! and Design 	United States	1635200 2/19/1991
Vector Laboratories, Inc.	Vectashield	United States	1755996 3/2/1993
Vector Laboratories, Inc.	Vectastain	United States	1220471 12/21/1982
Vector Laboratories, Inc.	Vector	United States	1259009 11/29/1983
Vector Laboratories, Inc.	Vectrex	United States	1542135 6/6/1989
TriLink BioTechnologies, LLC	CHROMALINK	United States	3268400 07/24/2007
TriLink BioTechnologies, LLC	MAGNALINK	United States	4542383 06/3/2014
TriLink BioTechnologies, LLC	NANOLINK	United States	4488606 02/25/2014
TriLink BioTechnologies, LLC	THE MODIFIED NUCLEIC ACID EXPERTS	United States	5024276 08/16/2016
TriLink BioTechnologies, LLC	OLIGOBUILDER	United States	5304533 10/10/2017

Owner	Mark	Country	Registration No. / Date
TriLink BioTechnologies, LLC	CLEANCAP	United States	5468487 05/15/2018
TriLink BioTechnologies, LLC	CLEANTAG	United States	5468481 05/15/2018
TriLink BioTechnologies, LLC	TRILINK	United States	5032541 08/30/2016
TriLink BioTechnologies, LLC	TRILINK BIOTECHNOLOGIES	United States	5082758 11/15/2016
TriLink BioTechnologies, LLC	TRILINK BIOTECHNOLOGIES & Design 	United States	5082759 11/15/2016
TriLink BioTechnologies, LLC	CLEANAMP	United States	5528329 7/31/2018
TriLink BioTechnologies, LLC	Design 	United States	5648745 01/08/2019



<b>Owner</b>	<b>Mark</b>	<b>Country</b>	<b>Registration No. / Date</b>
Vector Laboratories, Inc.	VIBRANCE	United States	6147993 09/08/2020
Cygnus Technologies, LLC <sup>1</sup>	ENDONUCLEASEGTP	United States	5899404 10/29/2019
Maravai Life Sciences, Inc.	SOLULINK	United States	4559923 07/01/2014

#### TRADEMARK APPLICATIONS

<b>Owner</b>	<b>Mark</b>	<b>Country</b>	<b>Application Serial No.</b>	<b>Filing Date</b>
Cygnus Technologies, LLC <sup>2</sup>	MOCKV	United States	90094653	08/05/2020

<sup>1</sup> Record ownership shows "Cygnus Technologies". Company to update record ownership at the U.S. Trademark Office.

<sup>2</sup> Record ownership shows "Cygnus Technologies". Company to update record ownership at the U.S. Trademark Office.

**SCHEDULE C**

**COPYRIGHTS**

None.